On September 29, 2026 Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, reported that a subset analysis of data from the company’s Phase 2 CLOVER WaM clinical trial that support the potential of iopofosine I 131 as a potential treatment option for Waldenström Macroglobulinemia (WM) patients who are refractory or resistant to BTK inhibitor therapy will be highlighted in a presentation at the upcoming International Workshop for Waldenström Macroglobulinemia (IWWM) taking place October 14 – 16, 2026 in Palm Springs, California.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We are pleased to present these data from the CLOVER-WaM study at IWWM and share additional evidence supporting the potential of iopofosine I 131 to address a significant unmet need for patients with WM. This analysis evaluated patients who received iopofosine I 131 immediately following BTK inhibitor therapy after at least two prior lines of treatment, representing a particularly challenging, heavily pretreated population," said Jarrod Longcor, chief operating officer at Cellectar Biosciences. "We remain on-target to dose patients in the confirmatory Phase 3 clinical trial in early 2027 and to file our New Drug Application for accelerated approval in the first half of 2027. Given iopofosine I 131 has Breakthrough Therapy Designation, we expect a six-month review with a potential approval by the end of 2027."
Details of the upcoming poster presentation are as follows:
Title: "Iopofosine I 131 After BTK Inhibitors in Waldenström Macroglobulinemia: CLOVER-WaM Subgroup Efficacy and Safety"
Session #: 14
Date/Time: October 15, 2026, 4:00 PM
Location: Sierra-Ventura Hall
Presenter: Jarrod Longcor, Chief Operating Officer of Cellectar Biosciences
(Press release, Cellectar Biosciences, SEP 29, 2026, https://www.cellectar.com/investors/news-events/press-releases/detail/397/cellectar-biosciences-to-present-compelling-efficacy-data-from-phase-2-clover-wam-subset-analysis-of-iopofosine-i-131-in-patients-refractoryresistant-to-btk-inhibitor-therapy-at-international-workshop-for-waldenstrm-macroglobulinemia [SID1234671142])